8-K: Azenta Reports Mixed Q1 Results, Revenue Down 13% Despite Cost Reduction Efforts

Azenta's first quarter fiscal 2024 results show a 13% year-over-year revenue decline, although the company exceeded expectations on both top and bottom lines.

Summary

• Azenta reported a revenue of $154 million for the first quarter of fiscal year 2024, a 13% decrease compared to the same period last year.
• Organic revenue declined by 15% year-over-year, with a 1% tailwind from foreign exchange and a 1% contribution from acquisitions.
• The decline was primarily due to a significant drop in B Medical Systems revenue, which fell by 70%.
• The combined Sample Management Solutions and Multiomics business segments grew 2% organically.
• Excluding B Medical and Consumables & Instruments (C&I), revenue grew 5% organically.
• Diluted EPS from continuing operations was ($0.28), compared to ($0.15) in the first quarter of fiscal year 2023.
• Non-GAAP diluted EPS from continuing operations was $0.02, compared to $0.12 one year ago.
• Adjusted EBITDA was $5 million, with an adjusted EBITDA margin of 3.0%, down 370 basis points year-over-year.
• The company ended the quarter with $1.1 billion in cash, cash equivalents, restricted cash, and marketable securities.
• Free cash flow for the quarter was $15 million.
• Azenta repurchased 2.3 million shares for $113 million in the first quarter.
• The company intends to repurchase an additional $500 million in shares in fiscal year 2024.
• Full year fiscal 2024 revenue is expected to be in the range of $696 to $718 million, with organic revenue growth between 5% and 8%.
• Adjusted EBITDA margin expansion is expected to be approximately 300 basis points for the full year.
• Non-GAAP diluted earnings per share is expected to be in the range of $0.19 to $0.29 for the full year.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the company exceeding expectations and reiterating guidance, but the significant revenue decline and challenges in the B Medical Systems segment temper the overall outlook.

Positives

• The company exceeded expectations on both the top and bottom lines.
• Azenta achieved its third consecutive quarter of positive free cash flow.
• Cost reduction initiatives are showing positive results.
• The Sample Management Solutions and Multiomics segments showed organic growth.
• The company has a strong cash position with $1.1 billion in cash and marketable securities.
• Azenta is reiterating its full-year fiscal 2024 revenue and earnings guidance.

Negatives

• Overall revenue declined by 13% year-over-year.
• Organic revenue declined by 15% year-over-year.
• B Medical Systems revenue experienced a significant decline of 70% year-over-year.
• Diluted EPS from continuing operations was negative at ($0.28).
• Adjusted EBITDA margin decreased by 370 basis points year-over-year.
• Gross margin decreased by 160 basis points year-over-year.

Risks

• The company faces challenges in the B Medical Systems segment due to lower order volume.
• The Consumables and Instruments (C&I) business remains a headwind to growth.
• The company's performance is subject to the volatility of the life sciences markets.
• There are risks associated with obtaining components and materials from suppliers.
• The company is exposed to uncertainties in global political and economic conditions.
• There is a risk that the company may not be able to effectively reduce costs.

Future Outlook

Azenta is reiterating its full-year fiscal 2024 revenue guidance of $696 to $718 million, with organic revenue growth between 5% and 8%. Adjusted EBITDA margin expansion is expected to be approximately 300 basis points, and non-GAAP diluted earnings per share is expected to be in the range of $0.19 to $0.29.

Management Comments

• First quarter results came in ahead of expectations as we continued to deliver against our objectives on the top and bottom line, stated Steve Schwartz, President and CEO.
• We have made good progress on our cost reduction initiatives and are seeing the benefits of these actions.
• Even in a softer market environment, we remain positive about our position as we move through fiscal 2024, and we believe that the actions we have taken over the past several months will allow us to continue to outgrow the market.

Industry Context

The life sciences industry is experiencing volatility, which is impacting Azenta's performance, particularly in the B Medical Systems segment. However, the company's focus on cost reduction and growth in other segments positions it to potentially outperform the market.

Comparison to Industry Standards

• Azenta's performance is mixed when compared to industry peers. While the company has shown growth in its Sample Management Solutions and Multiomics segments, the significant decline in B Medical Systems revenue is a concern.
• Companies like Thermo Fisher Scientific and Danaher, which also operate in the life sciences sector, have shown more stable revenue growth in recent quarters, although they may not have the same exposure to the specific markets that Azenta serves.
• The 15% organic revenue decline is worse than many of its peers, however the company is showing positive free cash flow which is a positive sign.
• The company's adjusted EBITDA margin of 3.0% is lower than many of its peers, indicating a need for further cost optimization.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the share repurchase program and positive free cash flow.
• Employees may be impacted by cost reduction initiatives.
• Customers may experience changes in product availability or pricing due to supply chain challenges.
• Suppliers may face pressure to reduce costs or improve delivery times.

Next Steps

• Azenta will host an Investor Day on March 14, 2024, to outline the company's strategy and vision.
• The company will continue to execute its cost reduction initiatives.
• Azenta intends to repurchase an additional $500 million in shares in fiscal year 2024.

Key Dates

Keywords

Azenta, Life Sciences, Financial Results, Revenue, EBITDA, EPS, Sample Management Solutions, Multiomics, B Medical Systems, Organic Growth, Share Repurchase, Cost Reduction